Base on current edition of “Uptodate.com”, a website used by medical professionals in the US.
The combination of Gemzar+Xyloda is active for advanced billiary tumors.- in one study ,there were 22 objective responses(3 complete) out of 75 patients.
Favorable results have also been seen using Erlotinib,(an oral tyrosine kinase inhibitor) with partial response and 7 additional pt. remained progression-free at 6 months.
PS : Sorafenib is a multikinase inhibitor ;in a study done by Z.Guan in mice;published at 2009 GI Cancers Symposium,they found”complete tumor regression was achieved in 22.2% VS 0% in the untreated rats.” but please remember this was done in rats not HUMAN for cholangiocarcinoma.Sorafenib is FDA approved for hepatocellular carcinoma only,However ,it is not uncommon for “off label use” by MDs.